Table 3.
Clinicopathological and molecular characteristics of MSI-H and RNF43-mutated or RNF43 wild-type.
| Clinicopathologic characteristics | Number of patients, N (%) (N=296) | MSI-H and RNF43-mutated, N (%) (N=138) | MSI-H and RNF43 wild-type, N (%) (N=158) | P value |
|---|---|---|---|---|
| Age (median 57.94, range 13–95) | 0.3582 | |||
| Young (years <50) | 77 (26.01%) | 31 (22.46%) | 46 (29.11%) | |
| Intermediate (<70 years ≥50) | 112 (37.84%) | 57 (41.30%) | 55 (34.81%) | |
| Elder (years≥70) | 106 (35.81%) | 49 (35.51%) | 57 (36.08%) | |
| NA | 1 (0.34%) | 1 (0.72%) | 0 (0.00%) | |
| Gender | 0.8821 | |||
| Female | 150 (50.68%) | 72 (52.17%) | 78 (49.37%) | |
| Male | 144 (48.65%) | 65 (47.10%) | 79 (50.00%) | |
| NA | 2 (0.68%) | 1 (0.72%) | 1 (0.63%) | |
| Primary tumor location | 0.0235 | |||
| Right | 180 (60.81%) | 92 (66.67%) | 88 (55.70%) | |
| Left | 66 (22.30%) | 21 (15.22%) | 45 (28.48%) | |
| NA | 50 (16.89%) | 25 (18.12%) | 25 (15.82%) | |
| TNM stage | 0.6909 | |||
| I | 38 (12.84%) | 17 (12.32%) | 21 (13.29%) | |
| II | 112 (37.84%) | 57 (41.30%) | 55 (34.81%) | |
| III | 93 (31.42%) | 38 (27.54%) | 55 (34.81%) | |
| IV | 47 (15.88%) | 23 (16.67%) | 24 (15.19%) | |
| NA | 6 (2.03%) | 3 (2.17%) | 3 (1.90%) | |
| TUMOR_GRADE | 0.0835 | |||
| Well differentiated | 70 (23.65%) | 29 (21.01%) | 41 (25.95%) | |
| Moderately differentiated | 74 (25.00%) | 30 (21.74%) | 44 (27.85%) | |
| Moderate poorly differentiated | 13 (4.39%) | 4 (2.90%) | 9 (5.70%) | |
| Poorly differentiated | 59 (19.93%) | 36 (26.09%) | 23 (14.56%) | |
| NA | 80 (27.03%) | 39 (28.26%) | 41 (25.95%) | |
| TMB | 0.0196 | |||
| TMB-H | 271 (91.55%) | 132 (95.65%) | 139 (87.97%) | |
| TMB-L | 7 (2.36%) | 0 (0.00%) | 7 (4.43%) | |
| NA | 18 (6.08%) | 6 (4.35%) | 12 (7.59%) | |
| BRAF status | 0.6302 | |||
| BRAF mut | 110 (37.16%) | 49 (35.51%) | 61 (38.61%) | |
| BRAF wild-type | 186 (62.84%) | 89 (64.49%) | 97 (61.39%) |